fashion -WSS

fashion

author：hotspot 2025-10-02 21:00:04 - browse：35

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： 'Patient friction coefficient' can gauge a clinical trial's patient burden

Wikipedia

leisure time

WSS

Texas board proposes rules on abortion law emergency exemption

Steward Health Care expansion into Malta flopped

Independent physicians launch a new lobbying group

Yancopoulos of Regeneron works to expand Dupixent success

AI generated plenty of interest at JPM but not a lot of trust

Readout Newsletter: Illumina, CRISPR, Regeneron

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Medical records are filled with copy

Parkinson’s finding may lead to tests and, someday, treatments

Bright Health sells Medicare Advantage business to Molina

U.K. officials, researchers try to ease path for bespoke genetic treatments

United colonoscopy coverage change 'may cost lives,' doctors say

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Heart attack and stroke risk calculators need revising

The tragedy of Johnson & Johnson’s Covid vaccine

Wikipedia

NIH director takes cautious approach to Biden drug pricing priority

This gene therapy has record $4.25 million price. It's saved children.

Elizabeth Holmes banned from government health programs

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Think you might have Covid

Readout Newsletter: Merck, J&J, and long Covid

Wikipedia

leisure time

focus

hotspot